Each year in the U.S., nearly 2 million people are diagnosed with cancer. Globally, it’s the second leading cause of death—and by 2040, cases are projected to surge to 30 million, with more than 15 million deaths. At BeOne, we’re confronting this staggering challenge head-on. One year ago, we opened our flagship U.S. biologics manufacturing and clinical R&D facility in Hopewell, NJ—a major milestone in our mission to deliver innovative cancer medicines to more patients, faster. John V. Oyler, Co-Founder, Chairman and CEO, and Matthew Shaulis, GM, North America, reflect on the impact Hopewell is having, and how it’s advancing our bold mission to eradicate cancer through innovation, speed, and access.
We’re proud to announce our new name—BeOne Medicines—and our redomiciliation to Switzerland are now officially in effect. This marks a major milestone in our evolution as a company. BeOne is more than just a name change. It reflects who we are today as a leading global oncology company—and our bold ambition to redefine the future of cancer care. With a powerful oncology portfolio, a pioneering approach to clinical development, and expanded global manufacturing and commercial capabilities, we’re well-positioned to deliver transformative treatments to patients worldwide. As one, we’re uniting patients, families, scientists, physicians, governments, and other oncology public health stakeholders around the world in our shared mission against cancer. Read more in our press release: https://lnkd.in/g6KwbRcq #BeOneAgainstCancer #CancerCare #Oncology
Hopewell, NJ Employee: Gabby - Gabby talks about how everything we do at BeiGene is for the patients worldwide.
Hopewell, NJ Employee: Raheem - Raheem talks about BeiGene's manufacturing process that takes place in our new Hopewell, NJ facility.
Patient Story - Richard: Philadelphia Richard, a person that was living with cancer, tells his journey of being diagnosed and treated for cancer.
Our new facility in Hopewell, N.J., equipped with cutting-edge labs, advanced manufacturing capabilities, and a modern warehouse, is instrumental in delivering innovative medicines to patients around the world. With one of the largest and most impressive oncology pipelines in the industry, we’re well positioned to tackle 80% of the world’s cancers by incidence.
Our Q2 2024 earnings results are now available. Learn more about our commitment to making an impact for patients around the globe:
Watch the highlights from the grand opening of our flagship U.S. facility in Hopewell, N.J. last week. This state-of-the-art manufacturing and clinical R&D site will further strengthen our differentiated strategy which leverages speed, efficiency and technology to advance impactful medicines faster for hashtag#cancer patients worldwide. https://bit.ly/4c5EHVC
